Drug Approval | June 16, 2023
Briefs: Natco Pharma and Panacea Biotec
Panacea Biotec has announced the launch of its new range of high-quality pediatric food & nutritional products
Panacea Biotec has announced the launch of its new range of high-quality pediatric food & nutritional products
Collaboration to accelerate and de-risk clinical development of Nanopharmaceutics CNS portfolio
Investment enables development of revolutionary multi-omic platform using super-resolution imaging technology for earlier disease detection and accelerated discovery of therapeutics
Patent Term Extension is designed to restore some of the patent life lost during the regulatory review process for new drugs.
Pfizer is likely to show GSK significant competition
The application is in line with Innocan's strategy to expand the scope of its combined magnesium and cannabis topical solution
The randomised, multi-centre, evaluator blinded, parallel group, active controlled Phase 3 trial is being led by Lanhzou Biotechnique Development
UTD2 is the world's first oral epothilone microtubule inhibitor
The new lab will enable the Group to accelerate its efforts in this area, building new competencies and capabilities, as well as strengthening Solvay’s ability to develop breakthroughs in biodegradable-by-design solutions.
Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare, progressive chronic kidney disease
Subscribe To Our Newsletter & Stay Updated
